KALEIDO

preparations and substances for pharmaceutical and medical purposes, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis; therapeutic pharmaceuticals for medical use, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis